Quizartinib for treating AML in children: What are the safety data?

As a selective FLT3 inhibitor, Quizartinib has received widespread attention in the treatment of acute myeloid leukemia (AML), especially in high-risk patients carrying FLT3-ITD mutations. In adult patients, quizartinib has been approved by drug regulatory agencies in multiple countries and has been included in recommended use in multiple clinical guidelines. However, in the pediatric AML patient population, the use of quizartinib is still in the exploratory stage, especially its safety data are still in the process of accumulation and updating.

Currently, multiple overseas research institutions are conducting clinical trials of quizartinib in childrenAML, especially focusing on relapsed or refractory pediatric patients. Preliminary data show that the drug is relatively well tolerated in children, but strict dose control and dynamic monitoring are still needed. Metabolic rates and drug clearance vary among children in different age groups, requiring precise adjustment of dosage based on body weight and surface area. In terms of safety, prolongation of the QT interval, elevated liver enzymes, neutropenia, and mild gastrointestinal reactions are the main adverse events observed, but they are reversible in most cases and can be controlled by adjusting the dosage regimen.

Another issue that requires special attention is the differences in metabolic characteristics and organ tolerance of drugs during children's growth and development stages. Quizartinib may also have certain effects on non-target tissues during the targeted inhibition of FLT3 mutations. Therefore, when used in children, genetic testing, electrocardiogram monitoring, and liver and kidney function assessment must be combined to ensure a safe and controllable treatment process. In addition, some research institutions are exploring the combination of quizartinib and chemotherapy in children with AML to improve the treatment response rate and prolong disease-free survival.

Reference materials:https://go.drugbank.com/drugs/DB12874